Valuation: Vista Pharmaceuticals Limited

Market Cap 376M 4.01M 3.61M 3.34M 3.02M 5.71M 5.85M 40.02M 15.95M 201M 15.05M 14.73M 641M P/E 2024
-10.3x
P/E 2025 -13.6x
Enterprise Value 443M 4.72M 4.26M 3.93M 3.55M 6.72M 6.89M 47.11M 18.78M 237M 17.72M 17.34M 755M EV / Sales 2024
7.63x
EV / Sales 2025 8.85x
Free-Float
22.51%
Yield 2024 *
-
Yield 2025 -
09-12 Vista Pharmaceuticals Limited Announces Resignation of Barkha Jain from Company Secretary and Compliance Officer, Effective September 4, 2026 CI
08-14 Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
02-13 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
02-03 Vista Pharmaceuticals enters joint venture with Pleiades Therapeutics RE
13/08/25 Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
15/07/25 Vista Pharmaceuticals Limited announced that it has received INR 30.749994 million in funding CI
30/05/25 Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
18/02/25 Vista Pharmaceuticals Limited announced that it expects to receive INR 146.614482 million in funding CI
12/02/25 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
13/11/24 Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 CI
13/08/24 Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2024 CI
28/05/24 Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
10/02/24 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
1 day+1.24%
1 week+2.83%
Current month+5.31%
1 month+2.67%
3 months-4.11%
6 months-18.15%
Current year-19.66%
1 week 5.88
Extreme 5.88
6.95
1 month 5.32
Extreme 5.32
6.95
Current year 5.32
Extreme 5.32
8.87
1 year 5.32
Extreme 5.32
10.1
3 years 5.32
Extreme 5.32
19.32
5 years 5.32
Extreme 5.32
19.7
10 years 4.51
Extreme 4.51
56.15
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 76 01/01/2014
Director/Board Member 76 01/02/2010
Director/Board Member 87 15/06/1993
Change 5-day change 1-year change 3-year change Capi.($)
+1.24%+2.83%-31.45%-64.86% 4.24M
+0.35%+1.36%+45.38%+140.47% 1,280B
-0.13%+1.48%+44.67%+90.43% 675B
+0.37%+0.05%+31.00%+112.84% 521B
+0.68%+3.34%+39.39%+69.55% 386B
-0.59%-2.11%+61.83%+45.16% 363B
+1.01%+0.10%+28.23%+58.66% 301B
+0.53%-0.31%+3.55%+36.59% 286B
+0.62%-2.17%+38.31%+75.12% 253B
-0.67%-2.72%+38.49%+123.56% 211B
Average +0.52%-0.03%+29.94%+68.75% 428B
Weighted average by Cap. +0.63%+0.20%+39.61%+97.30%

Financials

2024 2025
Net sales 103M 1.1M 989K 913K 826K 1.56M 1.6M 10.95M 4.36M 55.1M 4.12M 4.03M 175M 101M 1.07M 968K 894K 809K 1.53M 1.57M 10.72M 4.27M 53.96M 4.03M 3.95M 172M
Net income -45.12M -481K -434K -401K -362K -685K -702K -4.8M -1.91M -24.16M -1.81M -1.77M -76.9M -46.49M -496K -447K -413K -373K -706K -723K -4.95M -1.97M -24.9M -1.86M -1.82M -79.23M
Net Debt 78.7M 839K 756K 699K 632K 1.2M 1.22M 8.37M 3.34M 42.15M 3.15M 3.08M 134M 66.71M 711K 641K 592K 535K 1.01M 1.04M 7.1M 2.83M 35.73M 2.67M 2.61M 114M
Projected Income Statement - Annual - Vista Pharmaceuticals Limited
Logo Vista Pharmaceuticals Limited
Vista Pharmaceuticals Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products. The Company offers over the counter and prescription generic drug products consisting of tablets, capsules and liquids covering various therapeutic categories. The Company has its United States Food and Drug Administration (USFDA) approved manufacturing facility in India and its marketing and distribution center in United States. Its products include tablet dosage forms and capsule dosage forms. The Company's tablet dosage forms in United States market include sulfamethoxazole & trimethoprim (400/80 mg) and acetaminophen (500 mg) film coated. The Company's tablet dosage forms in Non-United States market include aspirin (300, 325 & 500 mg), atenolol (50 & 100 mg), cotrimoxazole (480 mg), captopril (25 & 50 mg) and frusemide (40 mg). Its capsule dosage forms in Non-United States market include indomethacin (25 mg), piroxicam (10 & 20 mg) and nifedipine (10 mg).
Employees
30
Date Price Change Volume
12/11/26 ₹6.540 +1.24% 2,773
11/11/26 ₹6.460 -3.44% 8,915
09/11/26 ₹6.690 -0.74% 6,713
08/11/26 ₹6.740 +5.48% 574
06/11/26 ₹6.390 +0.47% 668
  1. Stock Market
  2. Stocks
  3. VISTAPH6 Stock